Neos Therapeutics, Inc
NEOS
NEOS was delisted on the 19th of March, 2021.
54 hedge funds and large institutions have $32.7M invested in Neos Therapeutics, Inc in 2019 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 10 increasing their positions, 15 reducing their positions, and 5 closing their positions.
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
8% more capital invested
Capital invested by funds: $30.4M → $32.7M (+$2.33M)
6% more funds holding
Funds holding: 51 → 54 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
33% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 15
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $23K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Russell Investments Group
London,
United Kingdom
|
+$871K |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$535K |
| 3 |
Renaissance Technologies
New York
|
+$388K |
| 4 |
Boston Partners
Boston,
Massachusetts
|
+$344K |
| 5 |
Goldman Sachs
New York
|
+$204K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$566K |
| 2 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$159K |
| 3 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$97.3K |
| 4 |
Citigroup
New York
|
-$90.7K |
| 5 |
WG
Winton Group
London,
United Kingdom
|
-$58.1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
BNP Paribas Financial Markets
Paris,
France
| $393 | -$7.9K | -5,264 | -95% |
|
|
PP
52
Paloma Partners
Greenwich,
Connecticut
| – | -$159K | -107,524 | Closed |
|
|
ARTA
53
A.R.T. Advisors
New York
| – | -$35K | -23,524 | Closed |
|
54
D.E. Shaw & Co
New York
| – | -$28K | -18,653 | Closed |
|
|
LP
55
LMR Partners
London,
United Kingdom
| – | -$22K | -15,038 | Closed |
|
56
Victory Capital Management
San Antonio,
Texas
| – | -$13K | -8,503 | Closed |
|
57
Morgan Stanley
New York
| – | -$1.95K | -1,300 | -81% |
|
58
Barclays
London,
United Kingdom
| – | -$65 | -43 | -36% |
|
|
APC
59
Aspire Private Capital
Cornelius,
North Carolina
| – | +$75 | +50 | New |
|
NEOS Hedge Fund Activity: Q4 2019 in Review
54 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Neos Therapeutics, Inc (NEOS) for Q4 2019, worth a combined $32.7M — up 7.7% from $30.4M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new NEOS positions and 5 closed out — a net gain of 3 holders — while 10 added to existing stakes and 15 trimmed.
The largest buyer was Russell Investments Group, opening a new position worth an estimated $871K. The largest seller was Sphera Funds Management, cutting an estimated $566K.
- 54 institutional investors held Neos Therapeutics, Inc (NEOS) as of Q4 2019, up from 51 in Q3 2019.
- Funds reported $32.7M of Neos Therapeutics, Inc stock for Q4 2019, up 7.7% quarter-over-quarter.
- 8 funds opened new Neos Therapeutics, Inc positions in Q4 2019 and 5 closed out, a net change of +3 holders.
- The largest Neos Therapeutics, Inc buyer in Q4 2019 was Russell Investments Group, an estimated $871K added.
- The largest Neos Therapeutics, Inc seller in Q4 2019 was Sphera Funds Management, an estimated $566K sold.
Based on aggregated 13F filings for Q4 2019.